Cargando…

EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates

Isavuconazole is the newest medical azole. We investigated EUCAST MICs for isavuconazole and seven comparators against 1,498 contemporary isolates (2016 to 2017). EUCAST susceptibility testing was performed. Isavuconazole MICs >2 dilution steps above the modal MIC were regarded as non-wild type f...

Descripción completa

Detalles Bibliográficos
Autores principales: Jørgensen, Karin Meinike, Astvad, Karen Marie Thyssen, Hare, Rasmus Krøger, Arendrup, Maiken Cavling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535523/
https://www.ncbi.nlm.nih.gov/pubmed/30910898
http://dx.doi.org/10.1128/AAC.00073-19
_version_ 1783421581647675392
author Jørgensen, Karin Meinike
Astvad, Karen Marie Thyssen
Hare, Rasmus Krøger
Arendrup, Maiken Cavling
author_facet Jørgensen, Karin Meinike
Astvad, Karen Marie Thyssen
Hare, Rasmus Krøger
Arendrup, Maiken Cavling
author_sort Jørgensen, Karin Meinike
collection PubMed
description Isavuconazole is the newest medical azole. We investigated EUCAST MICs for isavuconazole and seven comparators against 1,498 contemporary isolates (2016 to 2017). EUCAST susceptibility testing was performed. Isavuconazole MICs >2 dilution steps above the modal MIC were regarded as non-wild type for species without EUCAST epidemiological cutoff values (ECOFFs). CYP51A sequencing was performed when relevant. Pearson correlation analysis was adopted for comparing activity. Aspergillus accounted for 90% of mold and Candida accounted for 97% of yeast isolates. Thirty (9.3%) Aspergillus fumigatus isolates were classified as resistant, and 10 (3.1%) were classified as non-wild type. Thirteen (4%) were cross-resistant to other mold-active azoles. Target gene alterations were found in 10 (76.9%) isolates, including 4 (30.8%) of environmental origin (TR(34)/L98H [n = 3] and Trip(34)(3)/L98H [n = 1]). Six Aspergillus terreus isolates were resistant, including two (17%) with MICs of >2 mg/liter and M217I alterations. Modal MICs/MIC(50)s (milligrams per liter) against Candida spp. were ≤0.004/≤0.004 for C. albicans and C. dubliniensis, 0.008/0.008 for C. tropicalis, 0.016/0.016 for C. parapsilosis, 0.06/0.06 for C. glabrata, and 0.125/0.125 for C. krusei. A non-wild-type phenotype was observed for 6.6% of isolates (C. glabrata [11.8%] and C. tropicalis [12.3%], specifically). All of these isolates were nonsusceptible/non-wild type to fluconazole (96.1%) or voriconazole (86.2%). Low MICs were found for several other species, except Scedosporium apiospermum and Fusarium. The best correlation was found between isavuconazole and voriconazole overall but for A. terreus and Mucorales to itraconazole and posaconazole, respectively. Isavuconazole displayed broad in vitro activity. Acquired resistance was infrequent except in A. terreus, C. glabrata, and C. tropicalis and, when present, was associated with cross-resistance to other azoles. Revising the EUCAST breakpoints for A. fumigatus (defining an MIC of 2 mg/liter as intermediate [“I”]) would minimize major errors.
format Online
Article
Text
id pubmed-6535523
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-65355232019-06-03 EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates Jørgensen, Karin Meinike Astvad, Karen Marie Thyssen Hare, Rasmus Krøger Arendrup, Maiken Cavling Antimicrob Agents Chemother Susceptibility Isavuconazole is the newest medical azole. We investigated EUCAST MICs for isavuconazole and seven comparators against 1,498 contemporary isolates (2016 to 2017). EUCAST susceptibility testing was performed. Isavuconazole MICs >2 dilution steps above the modal MIC were regarded as non-wild type for species without EUCAST epidemiological cutoff values (ECOFFs). CYP51A sequencing was performed when relevant. Pearson correlation analysis was adopted for comparing activity. Aspergillus accounted for 90% of mold and Candida accounted for 97% of yeast isolates. Thirty (9.3%) Aspergillus fumigatus isolates were classified as resistant, and 10 (3.1%) were classified as non-wild type. Thirteen (4%) were cross-resistant to other mold-active azoles. Target gene alterations were found in 10 (76.9%) isolates, including 4 (30.8%) of environmental origin (TR(34)/L98H [n = 3] and Trip(34)(3)/L98H [n = 1]). Six Aspergillus terreus isolates were resistant, including two (17%) with MICs of >2 mg/liter and M217I alterations. Modal MICs/MIC(50)s (milligrams per liter) against Candida spp. were ≤0.004/≤0.004 for C. albicans and C. dubliniensis, 0.008/0.008 for C. tropicalis, 0.016/0.016 for C. parapsilosis, 0.06/0.06 for C. glabrata, and 0.125/0.125 for C. krusei. A non-wild-type phenotype was observed for 6.6% of isolates (C. glabrata [11.8%] and C. tropicalis [12.3%], specifically). All of these isolates were nonsusceptible/non-wild type to fluconazole (96.1%) or voriconazole (86.2%). Low MICs were found for several other species, except Scedosporium apiospermum and Fusarium. The best correlation was found between isavuconazole and voriconazole overall but for A. terreus and Mucorales to itraconazole and posaconazole, respectively. Isavuconazole displayed broad in vitro activity. Acquired resistance was infrequent except in A. terreus, C. glabrata, and C. tropicalis and, when present, was associated with cross-resistance to other azoles. Revising the EUCAST breakpoints for A. fumigatus (defining an MIC of 2 mg/liter as intermediate [“I”]) would minimize major errors. American Society for Microbiology 2019-05-23 /pmc/articles/PMC6535523/ /pubmed/30910898 http://dx.doi.org/10.1128/AAC.00073-19 Text en Copyright © 2019 Jørgensen et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Susceptibility
Jørgensen, Karin Meinike
Astvad, Karen Marie Thyssen
Hare, Rasmus Krøger
Arendrup, Maiken Cavling
EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates
title EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates
title_full EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates
title_fullStr EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates
title_full_unstemmed EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates
title_short EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates
title_sort eucast susceptibility testing of isavuconazole: mic data for contemporary clinical mold and yeast isolates
topic Susceptibility
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535523/
https://www.ncbi.nlm.nih.gov/pubmed/30910898
http://dx.doi.org/10.1128/AAC.00073-19
work_keys_str_mv AT jørgensenkarinmeinike eucastsusceptibilitytestingofisavuconazolemicdataforcontemporaryclinicalmoldandyeastisolates
AT astvadkarenmariethyssen eucastsusceptibilitytestingofisavuconazolemicdataforcontemporaryclinicalmoldandyeastisolates
AT harerasmuskrøger eucastsusceptibilitytestingofisavuconazolemicdataforcontemporaryclinicalmoldandyeastisolates
AT arendrupmaikencavling eucastsusceptibilitytestingofisavuconazolemicdataforcontemporaryclinicalmoldandyeastisolates